Form D · Biotechnology
Rasna Therapeutics Inc.
New York, NY · CIK 0001582249
Offering snapshot reported Dec 22, 2016 · SEC filing
- Reported sold
- $2.02M Offering amount: $10M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Dec 20, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 22, 2016 | Initial | $2,020,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-276930
Source: Form D, filed Dec 22, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Brancaccio | Director |
| Riccardo Dalla Favera | Director |
| Tiziano Lazzaretti | Executive |
| John Alex Martin | Director |
| Jim Mervis | Director |
| Alessandro Padova | Director |
| Kunwar Shailubhai | Director |
| James Tripp | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
420 Lexington Avenue Suite 2525
New York, NY, 10170
New York, NY, 10170